R9156

Raltitrexed

≥98% (HPLC), solid

• Synonym(s): L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl), ICI-D-1694, ZD-1694
• Empirical Formula (Hill Notation): C₂₁H₂₂N₄O₆S
• CAS Number: 112887-68-0
• Molecular Weight: 458.49
• UNSPSC Code: 12352200
• PubChem Substance ID: 329824044
• NACRES: NA.77

Properties

• Quality Level: 100
• Assay: ≥98% (HPLC)
• form: solid
• color: off-white to light yellow
• solubility: H₂O: ≥10 mg/mL; DMSO: ≥40 mg/mL
• originator: AstraZeneca
• storage temp.: 2-8°C
• SMILES string: O=C1NC(C)=NC2=C1C=C(CN(C3=CC=C(C(N[C@H](CCC(O)=O)C(O)=O)=O)S3)C)C=C2

Description

Biochem/physiol Actions

Raltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives. By inhibiting the formation of precursor pyrimidine nucleotides, raltitrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.

Features and Benefits

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Safety Information

• Pictograms: GHS06,GHS08
• Signal Word: Danger
• Hazard Statements: H300,H360
• Precautionary Statements: P201 - P301 + P310 + P330
• Hazard Classifications: Acute Tox. 2 Oral - Repr. 1B
• Storage Class Code: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• WGK: WGK 2
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves